Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Only the boxed-warning-related claim about thrombotic risk with premature discontinuation and spinal/epidural hematoma is supported by the provided FDA label excerpts. The other claims are not evaluated against (or supported by) the provided prescribing information content, so label alignment cannot be confirmed.
Category Scores
Accurate Statements
The risk of thrombotic events increases if XARELTO is discontinued prematurely, and epidural/spinal hematoma can occur in patients undergoing neuraxial anesthesia or spinal puncture with XARELTO, potentially resulting in long-term or permanent paralysis.
Supported by BOXED WARNING (A) and (B) and also by Warnings and Precautions sections 5.1 and 5.3 in the provided label text.
Unsupported Statements
Xarelto 20 mg is rivaroxaban, an anticoagulant medication.
No supporting prescribing information for drug composition/active ingredient or dosage strength was included in the provided label excerpts.
The generic version of Xarelto 20 mg is available.
Availability/market status is not addressed in the provided prescribing information excerpts.
Key patents protecting Xarelto have expired in the United States, allowing for the introduction of generic versions.
Patent status is not addressed in the provided prescribing information excerpts.
Multiple pharmaceutical companies have introduced generic versions of rivaroxaban, including the 20 mg dosage, following expiration of patent protections.
Generic manufacturer and patent-expiration claims are not addressed in the provided prescribing information excerpts.
Generic versions of Xarelto 20 mg offer a therapeutically equivalent alternative to branded Xarelto.
Therapeutic equivalence/AB rating is not addressed in the provided prescribing information excerpts.
Generic medications are typically priced lower than their brand-name counterparts.
Pricing/cost statements are not addressed in the provided prescribing information excerpts.
The availability of multiple generic manufacturers can lead to increased price competition, potentially further reducing costs for patients and healthcare systems.
Cost/market-competition statements are not addressed in the provided prescribing information excerpts.
Several pharmaceutical companies manufacture generic rivaroxaban.
Manufacturer list is not addressed in the provided prescribing information excerpts.
Generic rivaroxaban can be produced as bioequivalent versions of the medication after patent expiry.
Bioequivalence after patent expiry is not addressed in the provided prescribing information excerpts.
Additional regulatory exclusivities or secondary patents might exist for specific formulations, indications, or manufacturing processes.
Regulatory exclusivity/patent landscape statements are not addressed in the provided prescribing information excerpts.
Secondary patents or regulatory exclusivities could potentially delay or affect the market entry of generics.
Market-entry delay statements are not addressed in the provided prescribing information excerpts.
Challenges to these patents or their expiration would open the door for generic competition.
Patent litigation/competition claims are not addressed in the provided prescribing information excerpts.
Contradictions
Important Omissions
When discussing risks related to premature discontinuation and neuraxial anesthesia/puncture, the provided label also includes additional specifics (e.g., monitoring for neurological impairment; timing considerations such as not removing catheters before at least 2 half-lives and not administering the next dose earlier than 6 hours after removal). These details were not included in the AI response’s claim list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the key boxed-warning risk statement was supported, the broader response content contains many non-label claims (e.g., patent/generic availability/therapeutic equivalence) that are not supported by the provided label excerpts; this reduces reliability for label-based decision support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Most claims concern generic/patent/market factors not present in the provided prescribing information excerpts; only the boxed-warning-related safety claim is clearly supported.
Suggested Improvement
Restrict statements to what is explicitly covered in the provided FDA label text (e.g., boxed warning A/B and related Sections 5.1/5.3), or provide additional label excerpts supporting generic/active ingredient/availability assertions before including them.